Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

MiR-16 regulates crosstalk in NF-kB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages.

Khalife J, Ghose J, Martella M, Viola D, Rocci A, Troadec E, Terrazas C, Satoskar AR, Gunes EG, Dona A, Sanchez JF, Bergsagel PL, Chesi M, Pozhitkov A, Rosen S, Marcucci G, Keats JJ, Hofmeister CC, Krishnan A, Caserta E, Pichiorri F.

JCI Insight. 2019 Oct 8. pii: 129348. doi: 10.1172/jci.insight.129348. [Epub ahead of print]

2.

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.

Rustad EH, Misund K, Bernard E, Coward E, Yellapantula VD, Hultcrantz M, Ho C, Kazandjian D, Korde N, Mailankody S, Keats JJ, Akhlaghi T, Viny AD, Mayman DJ, Carroll K, Patel M, Famulare CA, Op Bruinink DH, Hutt K, Jacobsen A, Huang Y, Miller JE, Maura F, Papaemmanuil E, Waage A, Arcila ME, Landgren O.

Am J Hematol. 2019 Oct 1. doi: 10.1002/ajh.25641. [Epub ahead of print]

PMID:
31571261
3.

MYC dysregulation in the progression of multiple myeloma.

Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, Van Wier SA, Riggs DL, Ahmann G, Chesi M, Viswanatha DS, Kumar SK, Dispenzieri A, Gonzalez-Calle V, Kyle RA, O'Dwyer M, Rajkumar SV, Kortüm KM, Keats JJ; MMRF CoMMpass Network, Fonseca R, Stewart AK, Kuehl WM, Braggio E, Bergsagel PL.

Leukemia. 2019 Aug 22. doi: 10.1038/s41375-019-0543-4. [Epub ahead of print] No abstract available.

PMID:
31439946
4.

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Barwick BG, Neri P, Bahlis NJ, Nooka AK, Dhodapkar MV, Jaye DL, Hofmeister CC, Kaufman JL, Gupta VA, Auclair D, Keats JJ, Lonial S, Vertino PM, Boise LH.

Nat Commun. 2019 Apr 23;10(1):1911. doi: 10.1038/s41467-019-09555-6.

5.

Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.

Buettner R, Morales C, Caserta E, Troadec E, Gunes EG, Viola D, Khalife J, Li H, Keats JJ, Christofferson A, Wu X, Synold TW, Palmer J, Sanchez JF, Pozhitkov A, Vaidehi N, Marcucci G, Krishnan A, Rosenzweig MA, Pichiorri F, Rosen ST.

Blood Adv. 2019 Apr 9;3(7):1027-1032. doi: 10.1182/bloodadvances.2018027227. No abstract available.

6.

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma.

Ledergor G, Weiner A, Zada M, Wang SY, Cohen YC, Gatt ME, Snir N, Magen H, Koren-Michowitz M, Herzog-Tzarfati K, Keren-Shaul H, Bornstein C, Rotkopf R, Yofe I, David E, Yellapantula V, Kay S, Salai M, Ben Yehuda D, Nagler A, Shvidel L, Orr-Urtreger A, Halpern KB, Itzkovitz S, Landgren O, San-Miguel J, Paiva B, Keats JJ, Papaemmanuil E, Avivi I, Barbash GI, Tanay A, Amit I.

Nat Med. 2018 Dec;24(12):1867-1876. doi: 10.1038/s41591-018-0269-2. Epub 2018 Dec 6.

PMID:
30523328
7.

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.

Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K.

Blood. 2018 Nov 15;132(20):2154-2165. doi: 10.1182/blood-2018-05-849893. Epub 2018 Sep 4.

8.

Whole Exome Library Construction for Next Generation Sequencing.

Liang WS, Stephenson K, Adkins J, Christofferson A, Helland A, Cuyugan L, Keats JJ.

Methods Mol Biol. 2018;1706:163-174. doi: 10.1007/978-1-4939-7471-9_9. Review.

PMID:
29423798
9.

Whole Genome Library Construction for Next Generation Sequencing.

Keats JJ, Cuyugan L, Adkins J, Liang WS.

Methods Mol Biol. 2018;1706:151-161. doi: 10.1007/978-1-4939-7471-9_8. Review.

PMID:
29423797
10.

HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.

Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, Pawlyn C, Bright MD, Wardell CP, Keats JJ, De Billy E, Rye CS, Chessum NEA, Jones K, Morgan GJ, Eccles SA, Workman P, Davies FE.

Clin Cancer Res. 2018 May 15;24(10):2395-2407. doi: 10.1158/1078-0432.CCR-17-1594. Epub 2018 Feb 1.

11.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.

Mailankody S, Kazandjian D, Korde N, Roschewski M, Manasanch E, Bhutani M, Tageja N, Kwok M, Zhang Y, Zingone A, Lamy L, Costello R, Morrison C, Hultcrantz M, Christofferson A, Washington M, Boateng M, Steinberg SM, Stetler-Stevenson M, Figg WD, Papaemmanuil E, Wilson WH, Keats JJ, Landgren O.

Blood Adv. 2017 Sep 29;1(22):1911-1918. doi: 10.1182/bloodadvances.2017005934. eCollection 2017 Oct 10.

12.

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma.

Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE.

Cancer Cell. 2015 Oct 12;28(4):541-542. doi: 10.1016/j.ccell.2015.09.010. Epub 2015 Oct 12. No abstract available.

13.

An integrated framework for reporting clinically relevant biomarkers from paired tumor/normal genomic and transcriptomic sequencing data in support of clinical trials in personalized medicine.

Nasser S, Kurdolgu AA, Izatt T, Aldrich J, Russell ML, Christoforides A, Tembe W, Keifer JA, Corneveaux JJ, Byron SA, Forman KM, Zuccaro C, Keats JJ, Lorusso PM, Carpten JD, Trent JM, Craig DW.

Pac Symp Biocomput. 2015:56-67.

14.

Bringing RNA-seq closer to the clinic.

Van Keuren-Jensen K, Keats JJ, Craig DW.

Nat Biotechnol. 2014 Sep;32(9):884-5. doi: 10.1038/nbt.3017. No abstract available.

PMID:
25203037
15.

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.

Affer M, Chesi M, Chen WG, Keats JJ, Demchenko YN, Roschke AV, Van Wier S, Fonseca R, Bergsagel PL, Kuehl WM.

Leukemia. 2014 Aug;28(8):1725-1735. doi: 10.1038/leu.2014.70. Epub 2014 Feb 12.

16.

Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M; Multiple Myeloma Research Consortium, Getz G, Golub TR.

Cancer Cell. 2014 Jan 13;25(1):91-101. doi: 10.1016/j.ccr.2013.12.015.

17.

Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, Chung KC, Tiedemann RE.

Cancer Cell. 2013 Sep 9;24(3):289-304. doi: 10.1016/j.ccr.2013.08.009. Erratum in: Cancer Cell. 2015 Oct 12;28(4):541-2.

18.

Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.

Mohan P, Castellsague J, Jiang J, Allen K, Chen H, Nemirovsky O, Spyra M, Hu K, Kluwe L, Pujana MA, Villanueva A, Mautner VF, Keats JJ, Dunn SE, Lazaro C, Maxwell CA.

Oncotarget. 2013 Jan;4(1):80-93.

19.

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S, Middha S, Asmann Y, Schmidt J, Braggio E, Keats JJ, Fonseca R, Bergsagel PL, Craig DW, Carpten JD, Stewart AK.

Blood. 2012 Aug 2;120(5):1060-6. doi: 10.1182/blood-2012-01-405977. Epub 2012 Apr 23.

20.

Clonal competition with alternating dominance in multiple myeloma.

Keats JJ, Chesi M, Egan JB, Garbitt VM, Palmer SE, Braggio E, Van Wier S, Blackburn PR, Baker AS, Dispenzieri A, Kumar S, Rajkumar SV, Carpten JD, Barrett M, Fonseca R, Stewart AK, Bergsagel PL.

Blood. 2012 Aug 2;120(5):1067-76. doi: 10.1182/blood-2012-01-405985. Epub 2012 Apr 12.

21.

Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities.

Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM, Maurer MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig TE, Fonseca R.

Mod Pathol. 2012 May;25(5):651-60. doi: 10.1038/modpathol.2011.213. Epub 2012 Feb 3.

22.

Initial genome sequencing and analysis of multiple myeloma.

Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR.

Nature. 2011 Mar 24;471(7339):467-72. doi: 10.1038/nature09837.

23.

RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

Zhu YX, Tiedemann R, Shi CX, Yin H, Schmidt JE, Bruins LA, Keats JJ, Braggio E, Sereduk C, Mousses S, Stewart AK.

Blood. 2011 Apr 7;117(14):3847-57. doi: 10.1182/blood-2010-08-304022. Epub 2011 Feb 2.

24.

Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma.

Chng WJ, Gertz MA, Chung TH, Van Wier S, Keats JJ, Baker A, Bergsagel PL, Carpten J, Fonseca R.

Leukemia. 2010 Apr;24(4):833-42. doi: 10.1038/leu.2010.21. Epub 2010 Mar 11.

25.

Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM.

Blood. 2010 Apr 29;115(17):3541-52. doi: 10.1182/blood-2009-09-243535. Epub 2010 Jan 6.

26.

Spontaneous remission in a patient with t(4;14) translocation multiple myeloma.

Puig N, Trudel S, Keats JJ, Li ZH, Braggio E, Ahmann GJ, Zeng S, Fonseca R, Kukreti V.

J Clin Oncol. 2009 Nov 20;27(33):e194-7. doi: 10.1200/JCO.2009.22.0392. Epub 2009 Oct 5. Review. No abstract available.

PMID:
19805681
27.

Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes.

Steensma DP, Neiger JD, Porcher JC, Keats JJ, Bergsagel PL, Dennis TR, Knudson RA, Jenkins RB, Santana-Davila R, Kumar R, Ketterling RP.

Cancer Res. 2009 Oct 1;69(19):7518-23. doi: 10.1158/0008-5472.CAN-09-1428. Epub 2009 Sep 22.

28.

High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas.

Braggio E, Keats JJ, Leleu X, Wier SV, Jimenez-Zepeda VH, Schop RF, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R.

Clin Lymphoma Myeloma. 2009 Mar;9(1):39-42. doi: 10.3816/CLM.2009.n.009.

29.

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.

Braggio E, Keats JJ, Leleu X, Van Wier S, Jimenez-Zepeda VH, Valdez R, Schop RF, Price-Troska T, Henderson K, Sacco A, Azab F, Greipp P, Gertz M, Hayman S, Rajkumar SV, Carpten J, Chesi M, Barrett M, Stewart AK, Dogan A, Bergsagel PL, Ghobrial IM, Fonseca R.

Cancer Res. 2009 Apr 15;69(8):3579-88. doi: 10.1158/0008-5472.CAN-08-3701. Epub 2009 Apr 7.

30.

Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.

Tiedemann RE, Schmidt J, Keats JJ, Shi CX, Zhu YX, Palmer SE, Mao X, Schimmer AD, Stewart AK.

Blood. 2009 Apr 23;113(17):4027-37. doi: 10.1182/blood-2008-09-179796. Epub 2008 Dec 18.

31.

Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling.

Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, Vignali DA, Bergsagel PL, Karin M.

Nat Immunol. 2008 Dec;9(12):1364-70. doi: 10.1038/ni.1678. Epub 2008 Nov 9.

32.

Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, Dispenzieri A, Fonseca R, Ketterling RP, Knudson RA, Mulvihill EM, Tschumper RC, Wu X, Zeldenrust SR, Jelinek DF.

Blood. 2008 Sep 1;112(5):1931-41. doi: 10.1182/blood-2008-03-143040. Epub 2008 Jun 20.

33.

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Lai R, Reiman T.

Br J Haematol. 2008 Feb;140(3):295-302. Epub 2007 Dec 10.

PMID:
18076711
34.

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, Van Wier S, Tiedemann R, Shi CX, Sebag M, Braggio E, Henry T, Zhu YX, Fogle H, Price-Troska T, Ahmann G, Mancini C, Brents LA, Kumar S, Greipp P, Dispenzieri A, Bryant B, Mulligan G, Bruhn L, Barrett M, Valdez R, Trent J, Stewart AK, Carpten J, Bergsagel PL.

Cancer Cell. 2007 Aug;12(2):131-44.

35.

Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.

Keats JJ, Reiman T, Belch AR, Pilarski LM.

Leuk Lymphoma. 2006 Nov;47(11):2289-300. Review.

PMID:
17107900
36.

SSX cancer testis antigens are expressed in most multiple myeloma patients: co-expression of SSX1, 2, 4, and 5 correlates with adverse prognosis and high frequencies of SSX-positive PCs.

Taylor BJ, Reiman T, Pittman JA, Keats JJ, de Bruijn DR, Mant MJ, Belch AR, Pilarski LM.

J Immunother. 2005 Nov-Dec;28(6):564-75.

PMID:
16224274
37.
38.

Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Keats JJ, Maxwell CA, Taylor BJ, Hendzel MJ, Chesi M, Bergsagel PL, Larratt LM, Mant MJ, Reiman T, Belch AR, Pilarski LM.

Blood. 2005 May 15;105(10):4060-9. Epub 2005 Jan 27.

39.

RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma.

Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, Strachan E, Crainie M, Walker R, Belch AR, Pilarski LM, Barlogie B, Shaughnessy J Jr, Reiman T.

Blood. 2004 Aug 15;104(4):1151-8. Epub 2004 Apr 22.

PMID:
15105292
40.

RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability.

Maxwell CA, Keats JJ, Crainie M, Sun X, Yen T, Shibuya E, Hendzel M, Chan G, Pilarski LM.

Mol Biol Cell. 2003 Jun;14(6):2262-76. Epub 2003 Mar 20.

41.

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM.

Blood. 2003 Feb 15;101(4):1520-9. Epub 2002 Oct 3.

PMID:
12393535
42.

Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice.

Pilarski LM, Seeberger K, Coupland RW, Eshpeter A, Keats JJ, Taylor BJ, Belch AR.

Exp Hematol. 2002 Mar;30(3):221-8.

PMID:
11882359

Supplemental Content

Loading ...
Support Center